Yahoo
Frankfurt - Delayed Quote EUR

Genscript Biotech Corporation (G51.F)

3.7600 +0.1800 (+5.03%)
As of 8:03:49 AM GMT+1. Market Open.
View in AlphaSpace Currency in USD All numbers in thousands
Financial statements have been upgraded
A new layout with more detail in every statement.
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Total Revenue
844,969 959,526 594,486 560,480 625,698
Cost of Revenue
-405,685 -406,322 -322,361 -289,851 -321,615
Gross Profit
439,284 553,204 272,125 270,629 304,083
Selling, General and Administrative Expenses
-234,527 -228,058 -202,496 -186,960 -350,811
Research and Development Expenses
-79,352 -71,231 -53,789 -52,697 -390,096
Other Income/Expense, Operating
8,899 8,217 6,874 9,212 9,068
Operating Income/Expenses
-304,980 -291,072 -249,411 -230,445 -731,839
Total Operating Profit/Loss
134,304 262,132 22,714 40,184 -427,756
Total Net Finance Income/Expense
10,914 8,807 21,346 16,845 -51
Net Investment Income
-335,167 -342,699 -161,833 2,918 0
Irregular Income/Expenses
-397,772 -396,740 -52,069 -16,437 -12,629
Other Income/Expense, Non-Operating
-2,110 -2,033 -955 125,375 8,746
Non-Operating Income/Expenses, Total
-724,135 -732,665 -193,511 128,701 -3,934
Pretax Income
-589,831 -470,533 -170,797 168,885 -431,690
Provision for Income Tax
-47,370 -61,871 -2,977 -6,006 3,719
Net Income from Continuing Operations
-637,201 -532,404 -173,774 162,879 -427,971
Discontinued Operations
0 0 3,029,061 -518,000 --
Net Income after Extraordinary Items and Discontinued Operations
-637,201 -532,404 2,855,287 -355,121 -427,971
Non-Controlling/Minority Interests
490 -426 106,590 259,644 201,120
Net Income after Non-Controlling/Minority Interests
-636,711 -532,830 2,961,877 -95,477 -226,851
Net Income Available to Common Stockholders
-636,711 -532,830 2,961,877 -95,477 -226,851
Dilution to Earnings
-2,653 -2,653 0 -- --
Diluted Net Income Available to Common Stockholders
-639,364 -535,483 2,961,877 -95,477 -226,851
Basic EPS
-0.29 -0.25 1.40 -0.05 -0.11
Diluted EPS
-0.28 -0.25 1.36 -0.05 -0.11
Basic Weighted Average Shares Outstanding
2,181,600.6190 2,167,322.4030 2,121,285.4540 2,109,365.3280 2,097,134.7000
Diluted Weighted Average Shares Outstanding
2,205,661.7710 2,191,994.5260 2,178,301.7400 2,202,472.7070 2,097,134.7000
Income Statement, Supplemental
EBIT
-600,745 -479,340 -192,143 152,040 -431,639
EBITDA
-521,178 -405,301 -130,605 206,388 -367,391
12/31/2022 - 1/8/2016

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: